Solexa has come up in a few conversations recently. Obviously Solexa’s contribution to next-gen sequencing is difficult to ignore. But it’s also an interesting case study in how tortuous the route to commercial success can be.

So while I’ve written about Solexa before I thought it might be interesting to revisit the company. Particularly in light of some…

This post is for paying subscribers